Altium Capital Management

Aligned is a DeFi and Web3 infrastructure company.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.

Ocuphire Pharma is a clinical-stage biopharmaceutical company committed to the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. We are currently focused on providing a novel once-daily eye drop treatment option, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of our strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes, and to seek strategic partners for global commercialization.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.

Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.

Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.

Palisade Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases that currently lack effective medical solutions. The company focuses on researching and acquiring promising assets, scientific advancements, and technologies that can lead to meaningful therapies for patients. Through its commitment to addressing unmet medical needs, Palisade Bio aims to deliver novel therapeutic options that improve patient outcomes. The company is headquartered in Germantown, Maryland, and has a history of evolving its focus to enhance its therapeutic offerings.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

IMV Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and vaccines for infectious diseases, including COVID-19. Utilizing its proprietary delivery platform, the company targets immune cells within the human body to enhance their ability to attack cancer cells. Its lead candidate, DPX-Survivac, is a targeted T cell therapy that has shown promise in multiple Phase 1 and 1b trials for late-stage ovarian cancer and relapsed/refractory DLBCL. DPX-Survivac is currently undergoing Phase 2 clinical trials across six cancer types and is being evaluated in combination with Keytruda. IMV is also progressing with a DPX-based vaccine for COVID-19, developed in collaboration with experts in infectious diseases, and is working on a vaccine targeting the respiratory syncytial virus strain A. Founded in 2000 and based in Dartmouth, Canada, the company was previously known as Immunovaccine Inc. before rebranding in 2018.

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. Their products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.